Kudo M - Search Results

1

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW. Llovet JM, et al. Among authors: kudo m. J Clin Oncol. 2013 Oct 1;31(28):3509-16. doi: 10.1200/JCO.2012.47.3009. Epub 2013 Aug 26. J Clin Oncol. 2013. PMID: 23980090 Clinical Trial.

2

Early detection and curative treatment of early-stage hepatocellular carcinoma.

Kudo M. Kudo M. Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S144-8. doi: 10.1016/s1542-3565(05)00712-3. Clin Gastroenterol Hepatol. 2005. PMID: 16234064 Review.

3

Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy.

Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Minami Y, Ueshima K, Haji S. Takahashi S, et al. Among authors: kudo m. Oncology. 2007;72 Suppl 1:98-103. doi: 10.1159/000111714. Epub 2007 Dec 13. Oncology. 2007. PMID: 18087189

4

Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study.

Kudo M, Sakaguchi Y, Chung H, Hatanaka K, Hagiwara S, Ishikawa E, Takahashi S, Kitai S, Inoue T, Minami Y, Ueshima K. Kudo M, et al. Oncology. 2007;72 Suppl 1:132-8. doi: 10.1159/000111719. Epub 2007 Dec 13. Oncology. 2007. PMID: 18087194

5

Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy.

Kudo M. Kudo M. Oncology. 2008;75 Suppl 1:1-12. doi: 10.1159/000181865. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092266 Review.

6

Impact of interferon therapy after curative treatment of hepatocellular carcinoma.

Kudo M. Kudo M. Oncology. 2008;75 Suppl 1:30-41. doi: 10.1159/000173422. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092270

7

Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score.

Kitai S, Kudo M, Minami Y, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T. Kitai S, et al. Among authors: kudo m. Oncology. 2008;75 Suppl 1:83-90. doi: 10.1159/000173428. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092276

8

PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy.

Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Nagai T, Minami Y, Ueshima K. Takahashi S, et al. Among authors: kudo m. Oncology. 2008;75 Suppl 1:91-8. doi: 10.1159/000173429. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092277

9

Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma.

Ueshima K, Kudo M, Nagai T, Tatsumi C, Ueda T, Takahashi S, Hatanaka K, Kitai S, Ishikawa E, Inoue T, Hagiwara S, Minami Y, Chung H. Ueshima K, et al. Among authors: kudo m. Oncology. 2008;75 Suppl 1:106-13. doi: 10.1159/000173431. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092279

10

[Molecular targeted therapy for advanced hepatocellular carcinoma].

Kudo M. Kudo M. Nihon Shokakibyo Gakkai Zasshi. 2009 Dec;106(12):1712-26. Nihon Shokakibyo Gakkai Zasshi. 2009. PMID: 19966513 Review. Japanese. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,479 results

Search Page